Cash Flow Balaxi Pharma Cash flow Statement
Figures in Cr
Consolidated Cash Flow Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'20
Mar'19
No of Months
12
12
12
12
12
12
Profit Before Tax
28.00
2.00
56.00
54.00
8.00
2.00
Adjustment
7.00
-1.00
8.00
1.00
0.00
0.00
Changes In working Capital
-67.00
10.00
-46.00
-15.00
-22.00
-3.00
Cash Flow after changes in Working Capital
-31.00
11.00
18.00
39.00
-13.00
-1.00
Cash Flow from Operating Activities
-35.00
4.00
6.00
34.00
-14.00
-1.00
Cash Flow from Investing Activities
-21.00
-1.00
-10.00
-28.00
0.00
0.00
Cash Flow from Financing Activities
33.00
30.00
25.00
0.00
18.00
0.00
Net Cash Inflow / Outflow
-22.00
34.00
21.00
5.00
3.00
-1.00
Opening Cash & Cash Equivalents
62.00
28.00
7.00
1.00
0.00
1.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
39.00
62.00
28.00
7.00
3.00
0.00
Figures in INR Cr
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Balaxi Pharma
Figures in Cr
standaloned Cash Flow Results
Change(INR)
Change(%)
Profit Before Tax
5.29
33.24
-28.00
-84.09%
Adjustment
2.51
-3.01
5.00
183.39%
Changes In working Capital
-13.77
-24.12
11.00
42.91%
Cash Flow after changes in Working Capital
-5.96
6.11
-11.00
-197.55%
Cash Flow from Operating Activities
-7.6
-1.22
-6.00
-522.95%
Cash Flow from Investing Activities
-24.98
-0.15
-24.00
-16553.33%
Cash Flow from Financing Activities
17.21
2.71
15.00
535.06%
Net Cash Inflow / Outflow
-15.37
1.33
-16.00
-1255.64%
Opening Cash & Cash Equivalents
44.06
2.07
42.00
2028.50%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
28.68
3.41
25.00
741.06%
Cash Flow - Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is -818.69% vs -19.90% in Mar 2024
Mar'25
Mar'24
Change(%)
Cash Flow from Operating Activities
-35.00
4.87
-818.69%
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
